CDK4/6 Inhibition in Hormone Receptor-Positive mBC

Breast cancer experts discuss the survival benefit of CDK4/6 inhibitors over individual endocrine therapy alone, resistance to CDK4/6 inhibition, and the rise of ctDNA testing as seen in the plasmaMATCH trial.

댓글 

    다음 것